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Background/Aims: Cluster differentiation 44 standard iso-
form (CD44s) is a transmembrane glycoprotein. CD44s is a 
known prognostic factor in various cancers, due to its involve-
ment in tumor cell growth, invasion and metastasis. Its prog-
nostic role, however, is debated because it can be a positive 
or negative prognostic factor depending on tumor type and 
is still an ambiguous prognostic indicator in other cancers, 
especially hepatocellular carcinoma (HCC). We investigated 
the relationship between CD44s expression and survival in 
HCC patients. Methods: A total of 260 HCC samples were 
collected to generate a tissue microarray. Staining of the ar-
rays with a primary mouse CD44s monoclonal antibody was 
followed by evaluation of the relationship between CD44s 
expression and tumor differentiation. The effect of CD44s 
expression on patient survival was analyzed. Results: CD44s 
protein expression correlated with histological grade (most 
and worst Edmondson grade) of the HCC (p=0.029 and 
p=0.039, respectively) and adversely affected the disease 
free survival period based on univariate and multivariate 
analyses (p=0.038 and p=0.077, respectively). Conclu-
sions: High CD44s protein expression correlates with shorter 
disease free survival and poorly differentiated HCC. CD44s-
targeted therapy may be efﬁ  cacious for HCC treatment in the 
future. (Gut Liver 2011;5:204-209)
Key Words: Hepatocellular carcinoma; CD44s antigen; Pro-
tein microarrays
INTRODUCTION
Hepatocellular carcinoma (HCC) is ranked third in prevalence, 
behind stomach and lung, and mortality rate behind lung and 
stomach in the world.
1 There are some contributing factors to 
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prohibit better prognosis such as difficulty in early detection 
and frequent recurrent rate.
2 Therefore identification of predic-
tive marker for recurrence is still remained as critical subject. 
CD44 glycoprotein is integral membrane glycoprotein that 
recognizes and binds to hyaluronan, a component of extra-
cellular matrix glycan.
3 CD44s is known to play a role in the 
migration of some non-neoplastic cells such as lymphocytes 
and facilitates their homing to lymphoid organs.
2 There are two 
types of CD44 glycoprotein family-CD44s, the standard isoform
4 
and multiple spliced variants, CD44v.
5 CD44 has been known 
for having diverse effects on cellular function especially migra-
tion, adhesion and invasion and sometimes depending on site of 
tumor.
6,7 In addition, CD44s expression appears to be an indica-
tor of poor prognosis and clinical recurrence of many kinds of 
cancers, such as renal,
8 thyroid,
9 and colorectal cancer.
10 There 
are reports about relationship between expressions of CD44s 
protein and differentiation of tumor in other organs.
11,12 In cases 
of HCC, however, highly expressed CD44s protein has been cor-
related with poor prognostic factor and poorly differentiated 
tumor only in few reports.
11,13,14 In the present study, we studied 
relationship between expression of CD44s and tumor differ-
entiation with Edmondson grade systems (most and worst). In 
addition, expression of CD44s was investigated using tissue mi-
croarray and prognostic effect of CD44s protein on HCC. 
MATERIALS AND METHODS
1. Patients and samples
Paraffin block tumor and non-neoplastic liver tissues were 
obtained from the resected specimens of 260 hepatocellular 
carcinoma patients who underwent hepatectomy or segmentec-
tomy at the Hepatobiliary Department of Surgery of the Korean 
Cancer Center Hospital, Seoul, Korea between January 1, 1990 
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
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and December 25, 2003. Paraffin sections from 10 metastatic 
colorectal carcinomas in liver were used as immunohistochemi-
cal study of CD44s expression as control. 
2. Clinicopathological data
Tissue sections (5-μm thick) were deparaffinized in xylene, 
rehydrated in graded alcohol solution, and stained with hema-
toxylin and eosin solution. Histological examination of resected 
specimens was performed by a pathologist who was blinded to 
the CD44s expression result. Tumor differentiation was classi-
fied into four grades, from I to IV, according to criteria proposed 
by Edmondson and Steiner.
15 We estimated most and worst 
Edmondson grade and categorized them into two groups, high 
(higher than grade 3) and low grade (less than grade 2). The cut-
off value of high alpha-fetoprotein (AFP) designates serum AFP 
level above 200 ng/mL. Age group was divided into two groups, 
high and low group, which above 50 years old and below 50 
years old, respectively. The measurement of tumor size was 
done by gross examination directly or photographs. Histologic 
and cell types were categorized by World Health Organization 
classification of liver. Cell type was divided into two group, 
classic type and non-classic type. Histologic type was divided 
into trabecular group, which including microtrabecular and 
macrotrabecular type, and non-trabecular groups, which includ-
ing pseudo-glandular and compact pattern. If there were more 
than one tumor cell clusters in portal vein, then we counted 
positive of portal invasion. All patients were regularly followed 
in a hepatobiliary clinic and all clinicopathological and follow-
up data were collected prospectively in a computerized data-
base. 
3. Tissue microarray and immunohistochemistry
For each cancer case, all of the histologically well preserved 
target tissue (cancer and normal) was circled on the guide slides 
using different colored markers. No effort was made to distin-
guish between specific areas of available tumor (center versus 
periphery, depth of invasion, etc.). The formalin-fixed, paraffin-
embedded tissues corresponding to the histological sections 
were sampled from these marked regions using a specialized 
manual arraying instrument (Model MTA 1; Beecher Instru-
ments, Sun Prairie, WI, USA). Using this device, the marked 
slides were aligned with the original tissue block, and a needle 
was used to remove a cylindrical core (3 mm in diameter) from 
the original blocks (one to four cores of tumor were arrayed 
per original block); the core samples were then placed into an 
empty paraffin block. The tissue microarray (TMA) consisted 
of 59 malignant and 1 normal cores from HCC and normal 
control cases. Non-malignant tissues (normal liver parenchyma 
of metastatic colorectal carcinoma in liver) were placed as con-
trols for orientation at the top of each TMA block. In addition 
Fig. 1. Representative photomicro-
graphs showing CD44s expression. 
(A) Negative reactions for CD44s 
protein in normal hepatocytes. (B-D) 
Positive reactions for CD44s protein 
expression in grade 1 (B), grade 2 (C) 
and grade 3 (D) hepatocellular car-
cinomas, respectively (×200). CD44s 
staining is observed along the cyto-
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to the primary TMA set of 7 blocks, 4 duplicate sets were also 
constructed by additional sampling of each original block and 
positioning the tissues at identical coordinates. After the ar-
raying was completed, TMA blocks were completely sectioned 
at 5-μm thickness, yielding 20 slides from each block and im-
munohistochemical staining was performed. Non-specific bind-
ing was blocked with 1% bovine serum albumin (BSA) in 0.01 
mol/L citrate buffer (pH=6.0) for 30 minutes before exposure 
to the primary antibody for CD44s. After incubation at room 
temperature for 30 minutes with biotinylated anti-mouse IgG 
(Dako, Golstrup, Denmark) sections were incubated with avidin-
biotin peroxidase (1:200, Vectastain ABC kit; Vector Labora-
tories, Burlingame, CA, USA) for 60 minutes and rinsed again 
with PBS. They were counterstained with Mayer’s hematoxyline 
and mounted. The antibody used was primary mouse CD44s 
monoclonal antibody (1:250, Zymed Lab Inc., San Francisco, 
CA, USA). The slides were evaluated in a double-blind manner 
by two pathologists (H.S.R. and S.H.P.). CD44s immunoreac-
tivity along the cytoplasmic membrane tumor cells was only 
considered as positive reaction then Immunostaining was scored 
based on the percentage of stained cells into 4 categories: no 
expression (Score 0, 0% of stained cells), low expression (score 1, 
1-10% of stained cells), moderate expression (score 2, 11-50%) 
and high expression (score 3, >50% of stained cells). For statis-
tical purposes, staining scores were dichotomized as two groups 
on a scale of negative and positive scoring (Fig. 1).
4. Statistical analysis
Statistical analysis for the evaluation of relationship between 
CD44s immunostaining and clinicopathologic parameters was 
performed using Pearson’s chi-square test. We analyzed correla-
tion between CD44s expression of immunohistochemical stain-
ing and several clinicopathologic parameters, including tumor 
cell grade of HCC (most and worst Edmondson-Steiner grade), 
age, sex, TNM stage, AFP, tumor histologic type, and portal vein 
invasion. The influence of prognostic factors on tumor-related 
over all and disease free survival was assessed by Kaplan-Meier 
estimates and subgroups were compared by the log-rank test for 
univariate analysis. The multivariate Cox proportional hazard 
model was applied using a stepwise forward method to detect 
independent predictors of survival. Statistical analysis was 
carried out using SPSS for Windows (version 16.0; SPSS Inc., 
Chicago, IL, USA). Two-tailed p values of 0.05 or less were con-
sidered to be statistically significant.
RESULTS
Overall, 260 patients (median age, 52.1 years) were included 
in the study. Their clinical characteristics are given in Table 
1. The male to female ratio was 3.7. Data for disease-free and 
overall survival were available in all patients. Median follow-
up was 26±19 months (range, 2 to 137 months) for all patients 
together (n=260). Of them, 119 patients (45.7%) recurred and 37 
patients (14.2%) died of recurrent HCC, 22 patients (8.4%) died 
with hepatic failure, 4 patients (1.5%) due to respiratory failure, 
and 5 patients (1.7%) died with metastasis. 
1. Relationship between protein expression and clinico-
patholgic parameters
There was one or two significant relationship between each 
biological marker and clinicopathologic parameters. CD44s 
expression was associated with serum AFP level (p=0.004) and 
both most and worst Edmondson grades (p=0.029 and p=0.039). 
As both of Edmondson grade was getting higher, CD44s protein 
expression was increased. However, there was no significant 
correlation between CD44s expression and remaining clinico-
pathologic values (Table 1). 
2. Relationship between CD44s protein expression and sur-
vival 
As Edmondson grade system was known for time honored 
Table 1. Clinicopathologic Parameters of HCC according to CD44s 
Expression (n=260)
Parameter
CD44s protein expression (%)
p-value
Negative Positive
Age
  <50   61 (41.0)   36 (32.4) 0.161
  50≤   88 (59.0)   75 (67.6)
Sex
  Male 111 (74.5)   95 (85.6) 0.029
  Female   38 (25.5)   16 (14.4)
TMN staging
  Stage I, II, III 133 (89.2)   93 (83.8) 0.195
  Stage IV   16 (10.8)   18 (16.2)
AFP
  <200   74 (49.7)   74 (66.6) 0.004
  200≤   75 (50.3)   37 (33.4)
Histologic type
  Trabecular 141 (94.6) 103 (92.8) 0.372
  Non-trabecular     8 (5.4)     8 (7.2)
Edmondson grade (most)
  Low 109 (73.2)   67 (60.4) 0.029
  High   40 (26.8)   44 (39.6)
Edmondson grade (worst)
  Low   70 (46.9)   38 (34.2) 0.039
  High   79 (53.1)   73 (65.8)
Portal vein invasion
  No 102 (68.5)   72 (64.9) 0.543
  Yes   47 (31.5)   39 (35.1)
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prognostic factor and there was the relationship between CD44s 
and these classical grades system, we tried to evaluate correla-
tion of CD44s expression with overall and disease-free survival 
length. According to the result of relationship between Edmond-
son grade and survival lengths, the patients with low Edmond-
son grade showed significant longer surviving perio    d than those 
of higher grade (Tables 2 and 3). CD44s also showed shortened 
disease-free survival period in CD44s expressed patients group 
than negative expression group (p=0.038, Table 2, Fig. 2A). 
However no correlation between overall survival length and 
CD44s expression was identified (Table 3, Fig. 2B). There are 26 
patients (10%) who died with no evidence of tumor recurrence 
and we evaluated survival analysis after exclusion of these 
patients, which showed similar results in disease-free survival 
in univariate analysis (p=0.026). In multivariate analysis, most 
Edmondson grade (p=0.001) and portal vein invasion (p=0.001) 
were independent predictors of recurrence. CD44s was seen 
as marginally significant risk factor of recurrence of disease 
(p=0.077) (Table 4). Tumor size was also revealed as one of sig-
nificant independent variables for both overall and disease-free 
survival (p=0.004 and 0.015). Multivariate analysis of overall 
survival indicated no correlation between CD44s expression of 
the tumor (p=0.838) (Table 5). 
DISCUSSION
Up to date, liver cancer stem cell (CSC) has been identified by 
several cell surface antigens such as CD133, CD90 and CD44.
16,17 
Table 2. Disease-Free Survival in All Patients Using Kaplan-Meier 
Estimates
Median disease-free survival 
times, mo (95% CI)
p-value
Edmondson grade (most)
  Low grade 67.8 (53.4-82.4)
0.005
  High grade 46.3 (36.7-55.8)
Edmondson grade (worst)
  Low grade 65.0 (53.9-76.1)
<0.001
  High grade 35.9 (25.2-46.6)
CD44s expression
  Negative 62.1 (50.7-73.4)
0.038
  Positive 40.7 (35.7-59.7)
Portal vein invasion
  Negative 64.3 (53.5-75.1)
<0.001
  Positive 38.3 (25.2-51.2)
CI, confidence interval.
Table 3. Overall Survival in All Patients Using Kaplan-Meier Esti-
mates
Median overall survival times, 
mo (95% CI)
p-value
Edmondson grade (most)
  Low grade 116.3 (99.8-132.7)
<0.001
  High grade 63.9 (49.2-78.6)
Edmondson grade (worst)
  Low grade 119.2 (98.1-140.3)
0.002
  High grade 81.9 (64.3-99.5)
CD44s expression
  Negative 98.6 (83.2-114.0)
0.703
  Positive 97.2 (86.3-114.3)
Portal vein invasion
  Negative 115.7 (99.8-131.5)
<0.001
  Positive 66.9 (46.4-87.4)
CI, confidence interval.
Fig. 2. Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a 
negative prognosis (A), but there is no significant correlation between CD44s protein expression and overall survival (B).208  Gut and Liver, Vol. 5, No. 2, June 2011
CSCs are a newly identified subpopulation that possesses stem 
cell properties and are thought to be the cells that cause resis-
tance to chemotherapy and radiotherapy.
16 CD44s was shown to 
be a part of the CSC in other sites such as breast cancer and was 
known to contribute to poor prognosis.
18 
Up to date, we can identify only a few numbers of articles 
about CD44s in HCC.
14,19-21 Endo and Terada
14 presented their 
study of 107 HCC patients, which shows expression of series of 
CD44 protein correlated with reduced survival period (p<0.005). 
In addition they concluded CD44s was a single independent 
prognostic factor in multivariate survival analysis (hazards ratio, 
1.95 [1.00 to 3.78]). According to a previous data about CD44s 
protein expression in HCC, highly expressed CD44s molecule 
has been shown to be related with increased rate of vascular 
invasion.
13 They presented that increased CD44s expression in 
5 out of 6 patients showed vascular invasion opposed to the 
cases of CD44s negative showing vascular invasion in 5 out of 
21. Although number of case involved in the study was small, 
they resulted in significant difference between CD44s positive 
and negative groups (p<0.016). The present study was failed to 
found correlation between CD44s expression and vascular in-
vasion with portal vein. However we identified that this factor 
was significantly correlated with disease free survival and inde-
pendent factor in multivariate analysis (p=0.001). Beckebaum 
et al.
19 studied 53 HCC patients and role of CD44s expression in 
aspect of survival and other factors. They failed to present a sig-
nificant correlation between patient survival and CD44s expres-
sion, however expression of CD44s was shown as a significant 
predictable marker for lymph node metastasis (p<0.05). 
As almost of studies previously reported showed significance 
of CD44s in aspect of survival, the present study are also led to 
similar result. According to our result, CD44s was especially cor-
related with disease free survival of HCC, although we couldn’t 
find statistically significant correlation but marginal relationship 
between CD44s and disease-free survival (p=0.077). 
Our data presents another characteristic finding about re-
lationship between CD44s expression and Edmondson grade. 
Most and worst Edmondson grades had a statistically significant 
correlation with CD44s protein expression, respectively. Mattew 
et al.
13 also presented similar result as higher grade of tumor is 
related with upregulation of CD44s expression. Endo and Tera-
da
14 also concluded expression of CD44s correlated with poorly 
differentiated tumor in HCC. However, other studies from extra-
hepatic organs showed opposite results so there are still contro-
versial in relationship between expression of CD44s molecule 
and tumor grades.
22,23 
In this study, AFP had an inverse correlation with CD44s 
expression. Serum AFP level is widely used as a diagnostic tool 
or predictive factor in HCC and elevation of AFP level is consid-
ered as a poor prognostic factor as CD44s protein. Therefore we 
could speculate the correlation between two markers. Yang et 
al.
24 reported a similar result that serum level of AFP and CD44s 
protein expression in immunohistochemistry had an inverse 
correlation (p<0.001). Although serum AFP level is used as a 
sensitive marker for diagnosis of HCC, serum AFP level could 
be not elevated even in patients with obvious HCC.
25 Therefore 
CD44s could be used as a valuable predictive marker for tumor 
recurrence for the patients with normal serum AFP levels. 
Few authors have been tried to inhibit the activity of CD44s 
in other sites.
26,27 Gunia et al.
26 studied a function of CD44s by 
blocking of CD44s protein using anti-CD44s monoclonal an-
tibody in gliosarcoma cell line. They concluded that inhibition 
of CD44s protein function could be effective in preventing the 
tumor progression. However there was no data about blocking 
effect of anti-CD44s antibody on tumor progression in HCC. 
In conclusion, expression of CD44s tends to show an adverse 
prognostic effect in HCC. Also the expression depended on 
differentiation of tumor cells. We suggested that CD44s could 
effect on recurrence of HCC and be used as a candidate for tar-
geted therapy of HCC. 
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